Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon To Award Over $7 Mil. For Breast Cancer Prevention Research

This article was originally published in The Rose Sheet

Executive Summary

The Avon Foundation announced the recipients of more than $7 million in grants for breast cancer prevention research Oct. 4 at its Global Breast Cancer Survivors Day Celebration in New York

You may also be interested in...



Firms Can Indeed Do Well By Doing Good, “Cause” Marketing Studies Show

Twenty-five years after American Express coined the term "cause-related marketing" in connection with its contributions to the Statue of Liberty restoration project, research indicates that corporate involvement in programs with societal benefits continues to influence consumer choice

Profound Beauty Grows Virtual Presence To Avoid Going Mass

"Personalized" hair-care firm Profound Beauty is growing its presence online to attract new customers while preserving its status as a prestige brand

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel